Iceland· IS-EU/1/21/1603/004
Lumykras
A sotorasib product containing sotorasibum inn, registered in Iceland by Amgen Europe B.V.*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Sotorasib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX73 (sotorasib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Sotorasib · ATC L01XX73
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Sotorasibum INN
- Manufacturer
- Amgen Europe B.V.*
- Country
- Iceland (IS)
- ATC code
- L01XX73
- ATC class
- Sotorasib
- Defined daily dose
- 0.96 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sotorasib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandLUMYKRASAmgen Europe B.V.
- CzechiaLUMYKRASAmgen Europe B.V., Breda
- SpainLUMYKRAS 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAmgen Europe B.V.
- IrelandLUMYKRAS 240 mg film-coated tabletsAmgen Europe B.V.,
- NetherlandsLumykras 240 mg, filmomhulde tablettenAmgen Europe B.V.
- PolandLumykrasAmgen Europe B.V.
- BelgiumLumykras 240 mgAmgen Europe
- SwedenLUMYKRAS 240 mg Filmdragerad tablettAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Norway · Lumykras
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb80f11d-2853-4430-bf4f-7fd2f3ea3731 GET /v1/drugs/fb80f11d-2853-4430-bf4f-7fd2f3ea3731?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01XX73",
"marketed": false,
"strength": "240 mg",
"ma_number": "EU/1/21/1603/004",
"substance": "Sotorasibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45428"
}See everything about sotorasib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.